{"id":"placebo-tcs","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation"}]},"_chembl":{"chemblId":"CHEMBL2425825","moleculeType":"Small molecule","molecularWeight":"279.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo + TCS serves as the active control arm in phase 3 trials, where topical corticosteroids provide standard-of-care anti-inflammatory and immunosuppressive effects on skin conditions. The placebo component allows for blinding while TCS delivers the established therapeutic benefit expected from conventional treatment, enabling comparison of the investigational drug against this baseline.","oneSentence":"This is a control arm combining placebo with topical corticosteroid (TCS) therapy, used as a comparator in clinical trials to establish efficacy of an investigational treatment.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:34.286Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 dermatological trials (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT06311682","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"LEO Pharma","startDate":"2024-06-10","conditions":"Atopic Dermatitis","enrollment":195},{"nctId":"NCT06504160","phase":"PHASE1","title":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-10","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT06701331","phase":"PHASE3","title":"Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-12-22","conditions":"Atopic Dermatitis","enrollment":99},{"nctId":"NCT05559359","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-18","conditions":"Atopic Dermatitis, Eczema","enrollment":367},{"nctId":"NCT05704738","phase":"PHASE3","title":"A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-04-20","conditions":"Atopic Dermatitis","enrollment":532},{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":"Atopic Dermatitis","enrollment":1533},{"nctId":"NCT05724199","phase":"PHASE3","title":"A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-02-21","conditions":"Atopic Dermatitis","enrollment":746},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Atopic Dermatitis","enrollment":301},{"nctId":"NCT04202679","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-01-16","conditions":"Neurodermatitis","enrollment":160},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT06554847","phase":"PHASE3","title":"Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-09-23","conditions":"Dermatitis, Atopic, Eczema, Atopic","enrollment":400},{"nctId":"NCT03160885","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-06-12","conditions":"Atopic Dermatitis","enrollment":794},{"nctId":"NCT04587453","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2020-10-27","conditions":"Atopic Dermatitis","enrollment":106},{"nctId":"NCT03131648","phase":"PHASE3","title":"Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-05-30","conditions":"Atopic Dermatitis","enrollment":802},{"nctId":"NCT03761537","phase":"PHASE3","title":"Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-12-13","conditions":"Atopic Dermatitis","enrollment":277},{"nctId":"NCT05340049","phase":"NA","title":"Craniosacral Therapy Improves Infant Neurodevelopment","status":"COMPLETED","sponsor":"Clinica Gema Leon","startDate":"2021-12-18","conditions":"Child Development Disorder","enrollment":120},{"nctId":"NCT03942211","phase":"PHASE2","title":"A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag","status":"TERMINATED","sponsor":"Actelion","startDate":"2021-02-26","conditions":"Sarcoidosis-associated Pulmonary Hypertension","enrollment":10},{"nctId":"NCT04591743","phase":"NA","title":"Effectiveness of Transcranial Magnetic Stimulation (TMS) in Smoking Cessation, Combining Withdrawal Stimulation Followed by Maintenance Stimulation to Prevent Relapse.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-06-29","conditions":"Smoking Cessation","enrollment":79},{"nctId":"NCT05387707","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2022-08-16","conditions":"Pruritus, Atopic Dermatitis","enrollment":287},{"nctId":"NCT04953208","phase":"NA","title":"Remotely Non-invasive Brain Stimulation and Videogame to Alleviate Depression","status":"UNKNOWN","sponsor":"Mor Nahum","startDate":"2021-06-22","conditions":"Major Depressive Disorder","enrollment":114},{"nctId":"NCT03661138","phase":"PHASE3","title":"A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-27","conditions":"Atopic Dermatitis","enrollment":272},{"nctId":"NCT04250337","phase":"PHASE3","title":"Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-03","conditions":"Atopic Dermatitis","enrollment":228},{"nctId":"NCT03809663","phase":"PHASE2","title":"A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-03-15","conditions":"Atopic Dermatitis","enrollment":251},{"nctId":"NCT03948334","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-04","conditions":"Atopic Dermatitis","enrollment":123},{"nctId":"NCT03864627","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"Galapagos NV","startDate":"2019-03-25","conditions":"Atopic Dermatitis","enrollment":33},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT03345914","phase":"PHASE3","title":"Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-11-17","conditions":"Dermatitis, Atopic","enrollment":367},{"nctId":"NCT03733301","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-16","conditions":"Atopic Dermatitis","enrollment":329},{"nctId":"NCT01539096","phase":"PHASE1, PHASE2","title":"Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2011-07","conditions":"Stroke","enrollment":67},{"nctId":"NCT03100344","phase":"PHASE2","title":"Dose-ranging Study of Nemolizumab in Atopic Dermatitis","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-06-14","conditions":"Atopic Dermatitis","enrollment":226},{"nctId":"NCT02260986","phase":"PHASE3","title":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-09","conditions":"Atopic Dermatitis","enrollment":740},{"nctId":"NCT01639040","phase":"PHASE2","title":"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-07","conditions":"Atopic Dermatitis","enrollment":31},{"nctId":"NCT02340234","phase":"PHASE2","title":"A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05","conditions":"Atopic Dermatitis","enrollment":212},{"nctId":"NCT00121381","phase":"PHASE4","title":"Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-05","conditions":"Dermatitis, Atopic","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + TCS","genericName":"Placebo + TCS","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a control arm combining placebo with topical corticosteroid (TCS) therapy, used as a comparator in clinical trials to establish efficacy of an investigational treatment. Used for Control arm in phase 3 dermatological trials (specific indication unknown).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}